GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.
A Simple Blood Test Revolutionizes Alzheimer's Care: Why Roche's FDA Greenlight Changes Everything
The landscape of Alzheimer’s disease diagnosis and treatment is on the cusp of a dramatic transformation, thanks to the recent US Food and Drug Administration (FDA) clearance of a novel blood-based test developed by Roche. This approval is not just another step in medical technology; it signifies a potential "care paradigm shift" by introducing a simple, accessible tool that can efficiently evaluate the risk of Alzheimer’s disease pathology, particularly in primary care settings.
Beyond the "Black Box": Why Trust is the Ultimate Data Moat in Clinical Trial Recruitment
In the high-stakes world of clinical research, fixed machine learning models face a silent, inevitable threat: drift. As clinical practices shift, lab equipment is recalibrated, and patient populations evolve, static algorithms slowly degrade in accuracy. At Glassbury, we recognize that a "black box" approach is insufficient for the long-term challenges of Alzheimer's disease and related CNS conditions
The Blood Test "Smoke Detector": How AI Helps Family Doctors Spot Alzheimer’s Early
For decades, the path to an Alzheimer’s diagnosis has been a marathon, not a sprint. Patients and families often face months of uncertainty, navigating a complex web of specialist referrals, expensive PET scans, and invasive spinal taps. This delay is particularly challenging in primary care, where family doctors
Why New Alzheimer’s Treatments are Leaving Atypical Patients Behind
There is a massive blind spot in the current landscape of neurodegenerative care, and it’s one that should keep every health-tech developer awake at night. For decades, the public and medical consciousness has viewed Alzheimer’s disease through a single, narrow lens: the loss of memory. We imagine the grandmother who forgets a name or the father who loses his keys.
Lecanemab Real-World Safety: Duke Health Study Insights for Alzheimer’s Patients
For decades, the search for a way to slow down Alzheimer’s disease felt like chasing a horizon that never got closer. However, the arrival of anti-amyloid therapies like lecanemab has shifted the conversation from "what if" to "how." While clinical trials provide a controlled environment to test these drugs
Alzheimer’s & the GRK2 Enzyme: A Sleeping Key to Brain Energy
Discover how ETH Zurich researchers uncovered GRK2 enzyme aggregates as a novel Alzheimer's target, offering new hope for energy-restoring therapies.
Beyond Memory Loss: MRI Early Detection & 2026 Alzheimer's Advances
Groundbreaking 2026 research reveals structural brain changes precede amyloid plaques by 7+ years, transforming early detection, atypical Alzheimer's care, and targeted treatments.
Estrogen Receptor ERβ: A New Hope in the Fight Against Alzheimer’s in Women
If you look at the statistics for Alzheimer’s disease, one striking detail immediately stands out: almost two-thirds of all people living with Alzheimer's are women. For decades, scientists and doctors explained this gap simply by pointing to the calendar—women
Optimizing FDA Diversity Action Plan Compliance and Alzheimer’s Clinical Trial Matching Through Agentic AI
Discover how Glassbury AI leverages agentic NLP, SMART on FHIR protocols, and trust-centric community frameworks to solve Alzheimer's trial enrollment bottlenecks, de-risk asset beta, and automate FDA Diversity Action Plan (DAP) compliance under FDORA.